COVALENT DRUGS FORM LONG-LIVED TIES: IRREVERSIBLE INHIBITORS may provide unique benefits in drug development
The DOI matches its Crossref record.
Abstract
WHEN MOST small-molecule drugs meet a protein target, they nestle close to their intended. But the flirtatious relationship between drug and target is often fleeting, with the drug repeatedly drifting away and coming back. Like a teenager with no interest in settling down, the drug forms no permanent bond with its target. Some small molecules, however, do forge lasting ties. Their irreversible covalent bonds with proteins link compound and protein for good. The pharmaceutical industry has by and large avoided developing drugs interested in marriage and instead has pursued dating as a model of the drug-target interaction. Covalent drugs, companies have feared, would be so desperate for a mate that they would bond with the wrong proteins. The result would undoubtedly be toxicity. But now a growing group of researchers, in academe and in companies large and small, has begun pursuing covalent drug candidates. They say the strategy could provide high potency and selectivity—along ...
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Jackson, P. A., Widen, J. C., Harki, D. A., & Brummond, K. M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00788 · Cited by 588
Bauer, R. A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.005 · Cited by 534
Keap Calm, and Carry on Covalently
Wilson, A. J., Kerns, J. K., Callahan, J. F., & Moody, C. J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400224q · Cited by 171
Designing Irreversible Inhibitors—Worth the Effort?
González‐Bello, C. (2016) · ChemMedChem · doi:10.1002/cmdc.201500469 · Cited by 74
Metadata
- Authors
- GUTERMAN, L.
- Venue
- Chemical & Engineering News Archive
- Publisher
- American Chemical Society (ACS)
- Published
- 2011-09-05
- Volume
- 89
- Issue
- 36
- Pages
- 19-26
- ISSN
- 0009-2347 (ISSN-L)
- 2157-4936
- OpenAlex
- W2523153670
- Cited by
- 39
- References
- 0
- Type
- other
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: COVALENT DRUGS FORM LONG-LIVED TIES: IRREVERSIBLE INHIBITORS may provide unique benefits in drug development. https://app.cochat.ai/papers/10.1021/cen-v089n036.p019
- The paper
- GUTERMAN, L. (2011). COVALENT DRUGS FORM LONG-LIVED TIES: IRREVERSIBLE INHIBITORS may provide unique benefits in drug development. Chemical & Engineering News Archive. https://doi.org/10.1021/cen-v089n036.p019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.